A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Adam Mecca, MD, PhD
Yale University
Study Director - Adam Mecca, MD, PhD
Yale University (Stage 2)
Principal Investigator - Stephanie Post, MD
Spaulding Clinical Research (Stage 1)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Yale University
New Haven, Connecticut, United States
- Spaulding Clinical Research
West Bend, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Mar 2023
- Primary completion
- 15 Jul 2025
- Completion
- 15 Oct 2025
- Last update posted
- 6 Nov 2025
- Registered enrollment
- 51
- Registry id
- NCT05804383
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.